^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Proton pump inhibitor

    Related drugs:
    3d
    LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (clinicaltrials.gov)
    P3, N=310, Completed, Hanmi Pharmaceutical Company Limited | Recruiting --> Completed
    Trial completion • Head-to-Head
    8d
    A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers (clinicaltrials.gov)
    P1, N=74, Not yet recruiting, HK inno.N Corporation
    New P1 trial
    9d
    Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (clinicaltrials.gov)
    P3, N=88, Not yet recruiting, Tanta University
    New P3 trial
    9d
    Proton pump inhibitor increases intestinal epithelial paracellular permeability via the p38-MAPK/NF-κB signaling pathway. (PubMed, Mol Biol Rep)
    Although the absence of macroscopic intestinal lesions, PPI directly enhances intestinal epithelial paracellular permeability by decreasing the expression of the tight junction protein occludin, mediated by the p38-MAPK/NF-κB signaling pathway. These findings highlight that the potential and insidious side effects of PPI on the intestinal epithelial barrier warrant increased attention and caution from clinicians when prescribing PPIs for various gastrointestinal diseases.
    Journal
    |
    OCLN (Occludin)
    15d
    Omeprazole-Mediated Nanodelivery of Copper for Synchronous Remodeling of Copper Influx and Efflux in Cuproptotic Glioblastoma Therapy. (PubMed, Acta Biomater)
    To improve the permeability across blood-brain tumor barrier (BTB), minoxidil sulfate (MS) and T7 peptide are modified on Cu-OME SNDs to produce Cu-OME/MS@T7 SNDs. Meanwhile, the released OME further blocks copper efflux by suppressing ATP7A copper efflux transporter. Collectively, this work demonstrates the effectiveness of OME-mediated copper delivery in inducing copper dyshomeostasis and triggering cuproptosis, highlighting a promising therapeutic approach through synchronous remodeling of copper influx and efflux.
    Journal
    |
    ATP7A (ATPase Copper Transporting Alpha)
    |
    omeprazole
    17d
    Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Can Tho University of Medicine and Pharmacy
    New trial
    22d
    Pantoprazole Inhibited Metastasis and Angiogenesis Through Wnt/β-Catenin Signaling Pathway in Gastric Cancer Stem-Like Cells. (PubMed, Adv Biomed Res)
    We showed that pantoprazole may reduce the tumorigenicity of GCSCs through the Wnt signaling pathway. Therefore, pantoprazole may be an assistance treatment for gastric cancer therapy.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SUFU (SUFU Negative Regulator Of Hedgehog Signaling) • SMARCD1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 1)
    23d
    Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis (clinicaltrials.gov)
    P=N/A, N=210, Not yet recruiting, General Hospital of Shenyang Military Region
    New trial
    25d
    Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Indiana University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    25d
    Serum level of (interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-a, motilin (MTL), gastrin (GAS), pepsinogen (PG), after adjunctive treatment in patients with chronic atrophic gastritis. (PubMed, J Med Biochem)
    The effective treatment rate in patients of TG post-treatment (92.73%) was higher than CG (78.18%) (P<0.05). Matrine combined with omeprazole enteric-coated tablets significantly improved gastric mucosal histopathology, reduced inflammatory cytokine levels, enhanced gastric function, and increased the H. pylori eradication rate compared to omeprazole monotherapy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • GAST (Gastrin 2)
    |
    omeprazole
    28d
    FAST-HP: Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） (clinicaltrials.gov)
    P4, N=240, Not yet recruiting, First People's Hospital of Hangzhou
    New P4 trial
    28d
    TV-HP: Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication (clinicaltrials.gov)
    P2/3, N=240, Recruiting, First People's Hospital of Hangzhou
    New P2/3 trial • Head-to-Head